Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Biogen Idec Stories

2013-03-21 04:20:42

-- Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS1 EAST HANOVER, N.J., March 21, 2013 /PRNewswire/ -- New data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya(®) (fingolimod), the first oral disease modifying therapy approved to treat relapsing forms of multiple sclerosis (MS), significantly and consistently...

2013-03-20 20:22:52

Isis to host an investor event and live webcast at 7:30 am PT on Thursday, March 21 in San Diego CARLSBAD, Calif., March 20, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-SMN(Rx) in children with spinal muscular atrophy (SMA) were presented today at the 65(th) American Academy of Neurology (AAN) Annual Meeting by Dr. Claudia Chiriboga, from Columbia University Medical Center. In the presentation, Dr. Chiriboga...

2013-03-14 12:28:26

- Event and webcast scheduled on Thursday, March 21 at 7:30 a.m. Pacific Time CARLSBAD, Calif., March 14, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host an investor event and a live webcast on Thursday, March 21, 2013 at 7:30 a.m. Pacific Time to discuss the ISIS-SMN(Rx) Phase 1 data presented at the 2013 American Academy of Neurology Annual Meeting. Interested parties may register to attend the event in San Diego, CA, or access the...

2013-03-14 12:27:32

CHICAGO, March 14, 2013 /PRNewswire/ -- Zacks Equity Research highlights Cincinnati Financial (Nasdaq:CINF) as the Bull of the Day and ArcelorMittal (NYSE:MT) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Biogen Idec (Nasdaq:BIIB), Sanofi (NYSE:SNY) and Osiris Therapeutics (Nasdaq:OSIR). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Full analysis of all these stocks is available at http://at.zacks.com/?id=2678. Here is a synopsis of all five...

2013-03-12 08:29:00

CAMBRIDGE, Mass., March 12, 2013 /PRNewswire/ -- Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has added Katrine Bosley, a proven biotechnology industry leader, as an independent director. "Katrine brings a unique and important perspective to our board as we continue to advance our lead programs within this new class of vaccines," said Chip Clark, CEO of Genocea. "The breadth of her experience in creating strategic and business...

2013-03-11 13:22:56

The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. The study examined 319 people with MS who were treated with...

2013-03-11 12:24:22

CHICAGO, March 11, 2013 /PRNewswire/ -- Zacks Equity Research highlights Winnebago Industries, Inc. (NYSE:WGO) as the Bull of the Day and Gold Fields Limited (NYSE:GFI) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Biogen (Nasdaq:BIIB) and Novartis (NYSE:NVS). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Full analysis of all these stocks is available at http://at.zacks.com/?id=2678. Here is a...

2013-03-10 16:20:35

SAN DIEGO, March 10, 2013 /PRNewswire-USNewswire/ -- The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. The study...

2013-03-06 08:26:20

This announcement does not constitute an announcement of a firm intention to make an offer under the Irish Takeover Rules NEW YORK, March 6, 2013 /PRNewswire/ -- RP Management, LLC ("Royalty Pharma") remains committed to acquiring Elan (NYSE: ELN) on the terms set out in the Proposal Announcement of February 25, 2013, but continues to be disappointed that the Board of Elan has not engaged in discussions. Royalty Pharma is ready and able to move quickly to implement an offer and...

2013-02-28 08:30:19

- Conference Call Webcast Thursday, February 28, 12:00 p.m. ET at www.isispharm.com CARLSBAD, Calif., Feb. 28, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2012 financial results and reviewed the highlights of the year. Isis ended the year in a strong financial position significantly outperforming both its pro forma net operating loss (NOL) guidance and its cash guidance for the year. For the year ended December 31, 2012, Isis had an NOL of...